| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-10-31 |
| タイトル |
|
|
タイトル |
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma |
| 言語 |
|
|
言語 |
eng |
| DOI |
|
|
|
関連識別子 |
https://doi.org/10.1080/2162402X.2016.1204507 |
|
|
関連名称 |
10.1080/2162402X.2016.1204507 |
| キーワード |
|
|
主題 |
Metastatic melanoma, nivolumab, oligoclonal T cell expansion, PD-1, T-cell receptor sequencing |
| 資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 著者 |
Inoue, Hiroyuki
Park, Jae-Hyun
Kiyotani, Kazuma
Zewde, Makda
Miyashita, Azusa
Jinnin, Masatoshi
Kiniwa, Yukiko
Okuyama, Ryuhei
Tanaka, Ryota
Fujisawa, Yasuhiro
Kato, Hiroshi
Morita, Akimichi
Asai, Jun
Katoh, Norito
Yokota, Kenji
Akiyama, Masashi
Ihn, Hironobu
Fukushima, Satoshi
Nakamura, Yusuke
|
| 信州大学研究者総覧へのリンク |
|
|
氏名 |
Okuyama, Ryuhei |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.ZpfNHFSF.html |
| 出版者 |
|
|
出版者 |
TAYLOR & FRANCIS INC |
| 引用 |
|
|
内容記述 |
ONCOIMMUNOLOGY.5(9):e1204507(2016) |
| 書誌情報 |
ONCOIMMUNOLOGY
巻 5,
号 9,
p. e1204507,
発行日 2016-08-26
|
| 抄録 |
|
|
内容記述 |
Immune checkpoint inhibitors blocking the interaction between programmed death-1 (PD-1) and PD-1 ligand-1 (PD-L1) are revolutionizing the cancer immunotherapies with durable clinical responses. Although high expression of PD-L1 in tumor tissues has been implicated to correlate with the better response to the anti-PD-1 therapies, this association has been controversial. In this study, to characterize immune microenvironment in tumors, we examined mRNA levels of immune-related genes and characterized T cell repertoire in the tumors of 13 melanoma patients before and after nivolumab treatment. We found that, in addition to the PD-L1 (p = 0.03), expression levels of PD-1 ligand-2 (PD-L2), granzyme A (GZMA) and human leukocyte antigen-A (HLA-A) in the pre-treatment tumors were significantly higher (p = 0.04, p = 0.01 and p = 0.006, respectively) in responders (n = 5) than in non-responders (n = 8). With nivolumab treatment, tumors in responders exhibited a substantial increase of CD8, GZMA and perforin 1 (PRF1) expression levels as well as increased ratio of TBX21/GATA3, suggesting dominancy of helper T cell type 1 (Th1) response to type 2 (Th2) response. T cell receptor β (TCR-β) repertoire analysis revealed oligoclonal expansion of tumor-infiltrating T lymphocytes (TILs) in the tumor tissues of the responders. Our findings suggest that melanoma harboring high PD-1 ligands (PD-L1 and PD-L2), GZMA and HLA-A expression may respond preferentially to nivolumab treatment, which can enhance Th1-skewed cellular immunity with oligoclonal expansion of TILs. |
| 資源タイプ（コンテンツの種類） |
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
2162-4011 |
| PubMed |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
https://www.ncbi.nlm.nih.gov/pubmed/27757299 |
|
|
関連名称 |
27757299 |
| 権利 |
|
|
権利情報 |
© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC© Hiroyuki Inoue, Jae-Hyun Park, Kazuma Kiyotani, Makda Zewde, Azusa Miyashita, Masatoshi Jinnin, Yukiko Kiniwa, Ryuhei Okuyama, Ryota Tanaka, Yasuhiro Fujisawa, Hiroshi Kato, Akimichi Morita, Jun Asai, Norito Katoh, Kenji Yokota, Masashi Akiyama, Hironobu Ihn, Satoshi Fukushima, and Yusuke Nakamura. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000385528200006 |
Intratumoral expression levels of PD L1 GZMA and HLA A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic.pdf
